Nasdaq, S&P 500 Futures Rise As Quantum Stocks Stay Red-Hot, All Eyes On Warsh Fed Swearing-In: Why IBM, RGTI, QBTS, INFQ, AMD, RKLB Are In Focus

U.S. stock futures rose 0.3%-0.5% as investors reacted to a $2 billion federal push into quantum computing, which added nearly $5 billion in sector market value on Thursday. IBM gained another 4% premarket, while Rigetti, D-Wave, and Infleqtion were up about 10% on proposed federal grants; AMD rose 2% and Rocket Lab climbed 4% on a $90 million Space Force contract. Markets are also watching today’s consumer sentiment data and Kevin Warsh’s Fed swearing-in.

Analysis

This is less a pure “quantum beta” trade than a state-backed industrial policy signal that changes the probability distribution for domestic compute supply chains. The immediate winners are the names with a credible path to government validation, but the second-order beneficiary is the entire U.S. advanced packaging, RF, cryo, and test-equipment ecosystem; if Washington is serious about onshoring quantum hardware, the bottleneck shifts from idea generation to manufacturing yield and systems integration. That tends to favor scaled incumbents with balance sheets and procurement access over smaller pure-plays that re-rate fastest but can’t absorb execution risk.

The move also creates a classic crowdedness problem: once retail and momentum capital pile into a small set of listed quantum proxies, the trade becomes more sensitive to grant timing, press releases, and dilution than to fundamentals. Over the next 1-6 weeks, expect very high gap risk on any delay, clarification, or perceived favoritism in award size; the underlying businesses still won’t have changed, but positioning will. The cleanest hedge against the enthusiasm is to fade the weakest balance-sheet names on strength, because the cost of capital remains the real constraint even in a policy tailwind.

AMD’s reaction is interesting because it suggests investors are extrapolating the same AI infrastructure scarcity into compute names broadly, but that logic is more fragile than the quantum trade. If enterprise and sovereign spending really accelerates, the first-order winners are still the infrastructure suppliers with supply certainty and pricing power; if growth cools, high-multiple semis can de-rate quickly while policy beneficiaries keep their narrative premium. RKLB sits in a different bucket: defense budget visibility is improving, but the stock is now more exposed to “good news already priced in” than to the contract itself.

Consensus is probably underestimating how much of this is a sentiment and liquidity event rather than an immediate earnings event. The market can keep paying up for strategic optionality for months, but the inflection point will be when investors ask which of these firms can translate government dollars into recurring gross profit without repeated capital raises. That is where the dispersion between IBM and the smaller quantum names should widen materially.

Key Decisions for Investors

• Go long IBM vs short RGTI/QBTS on a 1-3 month horizon: IBM has policy credibility, scale, and less dilution risk; the smaller names have more upside if sentiment extends, but materially worse downside if funding enthusiasm cools.
• Sell upside into the quantum rally via short-dated call spreads on RGTI or QBTS: favorable if the group mean-reverts after the initial policy spike; risk is another grant headline, so keep size small and duration under 30 days.
• Initiate a tactical long AMD only on intraday pullbacks, not momentum breaks: the trade works if broader AI capex remains sticky, but upside is likely capped unless the market gets incremental supply-chain evidence.
• For RKLB, prefer a buy-the-dip approach over chasing the open: the contract is supportive over 3-6 months, but near-term upside is vulnerable to “sell the news” flow once event-driven buyers step in.
• Monitor for follow-through in semiconductor capital equipment and packaging names over the next 2-4 weeks; if the policy theme broadens, that basket may offer a cleaner risk/reward than the headline quantum names.